Indication intelligence, analysis and sector perception

Opexa Therapeutics (OPXA) reduces workforce by 40%

November 2, 2016 9:04am

After the negative P2b Abili-T clinical trial top-line results; OPXA closed DOWN another -$0.04 to $0.81 and it’s NOT ended - $0.50 and coming...

OPXA reduces operating expenses and conserve cash resources, on October 26, 2016, OPXA's reduced 20 current full-time employees.

· The workforce reduction is effective immediately.

· OPXA estimates that it will incur incremental aggregate cash charges of approximately $95 K associated with this workforce reduction.

OPXA also announced that it had accepted the resignation of Donna Rill, the Chief Development Officer, with such resignation to be effective as of 11/4.

The Bottom Line: A sad ending but, they, OPXA won’t be the only VICTIM.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.